PT  - JOURNAL ARTICLE
AU  - Sudre, Carole H.
AU  - Lee, Karla A.
AU  - Lochlainn, Mary Ni
AU  - Varsavsky, Thomas
AU  - Murray, Benjamin
AU  - Graham, Mark S.
AU  - Menni, Cristina
AU  - Modat, Marc
AU  - Bowyer, Ruth C E
AU  - Nguyen, Long H.
AU  - Drew, David A.
AU  - Joshi, Amit D.
AU  - Ma, Wenjie
AU  - Guo, Chuan-Guo
AU  - Lo, Chun-Han
AU  - Ganesh, Sajaysurya
AU  - Buwe, Abubakar
AU  - Pujol, Joan Capdevila
AU  - du Cadet, Julien Lavigne
AU  - Visconti, Alessia
AU  - Freidin, Maxim B
AU  - El-Sayed Moustafa, Julia S.
AU  - Falchi, Mario
AU  - Davies, Richard
AU  - Gomez, Maria F.
AU  - Fall, Tove
AU  - Cardoso, M. Jorge
AU  - Wolf, Jonathan
AU  - Franks, Paul W.
AU  - Chan, Andrew T.
AU  - Spector, Tim D.
AU  - Steves, Claire J
AU  - Ourselin, Sébastien
TI  - Symptom clusters in Covid19: A potential clinical prediction tool from the COVID Symptom study app
AID  - 10.1101/2020.06.12.20129056
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.12.20129056
4099  - http://medrxiv.org/content/early/2020/06/16/2020.06.12.20129056.short
4100  - http://medrxiv.org/content/early/2020/06/16/2020.06.12.20129056.full
AB  - As no one symptom can predict disease severity or the need for dedicated medical support in COVID-19, we asked if documenting symptom time series over the first few days informs outcome. Unsupervised time series clustering over symptom presentation was performed on data collected from a training dataset of completed cases enlisted early from the COVID Symptom Study Smartphone application, yielding six distinct symptom presentations. Clustering was validated on an independent replication dataset between May 1-May 28th, 2020. Using the first 5 days of symptom logging, the ROC-AUC of need for respiratory support was 78.8%, substantially outperforming personal characteristics alone (ROC-AUC 69.5%). Such an approach could be used to monitor at-risk patients and predict medical resource requirements days before they are required.One sentence summary Longitudinal clustering of symptoms can predict the need for respiratory support in severe COVID-19.Competing Interest StatementZoe Global Limited co-developed the app pro bono for non-commercial purposes. Investigators received support from the Wellcome Trust, the MRC/BHF, EU, NIHR, CDRF, and the NIHR-funded BioResource, Clinical Research Facility and BRC based at GSTT NHS Foundation Trust in partnership with KCL. RD, JW, JCP, AB, SG and JLduC work for Zoe Global Limited and TDS and PWF are consultants to Zoe Global Limited. LHN, DAD, PWF and ATC previously participated as investigators on a diet study unrelated to this work that was supported by Zoe Global Ltd.Funding StatementZoe provided in kind support for all aspects of building, running and supporting the app and service to all users worldwide. Support for this study was provided by the NIHR-funded Biomedical Research Centre based at GSTT NHS Foundation Trust. This work was supported by the UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare. Investigators also received support from the Wellcome Trust, the MRC/BHF, Alzheimer's Society, EU, NIHR, CDRF, and the NIHR-funded BioResource, Clinical Research Facility and BRC based at GSTT NHS Foundation Trust in partnership with KCL. ATC was supported in this work through a Stuart and Suzanne Steele MGH Research Scholar Award. CM is funded by the Chronic Disease Research Foundation and by the MRC AimHy project grant. LHN, DAD, ADJ, ADS, CG, WL are supported by the Massachusetts Consortium on Pathogen Readiness (MassCPR) and Mark and Lisa Schwartz. The work performed on the Swedish study is supported by grants from the Swedish Research Council, Swedish Heart-Lung Foundation and the Swedish Foundation for Strategic Research (LUDC-IRC 15-0067). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In the UK, the App Ethics has been approved by KCL ethics Committee REMAS ID 18210, review reference LRS-19/20-18210 and all subscribers provided consent. In Sweden, ethics approval for the study was provided by the central ethics committee (DNR 2020-01803).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this study is available to bona fide researchers through UK Health Data Research using the following link https://healthdatagateway.org/detail/9b604483-9cdc-41b2-b82c-14ee3dd705f6